Access to autologous cellular immunotherapies in Medicare Part B. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022.
2025 · 2nd Quarter (Apr 1 - June 30)
DENDREON PHARMACEUTICALS, LLC
Filed by DENDREON PHARMACEUTICALS, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Aug 19, 2025
- Income
- Not reported
- Expenses
- $58,787.00
- Registrant
- DENDREON PHARMACEUTICALS, LLC
- Filing UUID
- 73e9593b-ce1f-40b2-89cd-d7ad4ade10f3
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.